Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Xenon Pharmaceuticals Inc. (XENE)
|
Add to portfolio |
|
|
|
| Price: |
$30.01
| | Metrics |
| OS: |
64.1
|
M
| |
-25
|
% ROE
|
| Market cap: |
$1.93
|
B
| |
-24
|
% ROIC
|
|
Net cash:
|
$64.6
|
M
| |
$1.01
|
per share
|
|
EV:
|
$1.86
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($138)
|
M
| |
|
|
|
EBIT
|
($140)
|
M
| |
|
|
| EPS |
($2.54)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 9.4 | 18.4 | 32.2 | 6.8 | 1.1 | 0.7 | 1.8 | 15.6 |
| Revenue growth | -48.8% | -42.7% | 371.0% | 540.0% | 44.2% | -59.0% | -88.4% | -45.1% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 0.4 | 0.0 | 0.0 |
| Gross profit | 9.4 | 18.4 | 32.2 | 6.8 | 0.0 | 0.3 | 1.8 | 15.6 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 0.0% | 42.0% | 100.0% | 100.0% |
| Selling, general and administrative | 138.6 | 97.4 | 63.5 | | | | | |
| Research and development | | | | 38.8 | 23.6 | 25.6 | 19.8 | 15.2 |
| General and administrative | | | | 10.8 | 8.4 | 7.3 | 6.8 | 9.8 |
| EBIT | -121.4 | -78.8 | -26.9 | -42.8 | -38.0 | -32.6 | -24.8 | -9.4 |
| EBIT margin | -1286.5% | -427.3% | -83.6% | -627.0% | -3565.1% | -4402.0% | -1376.4% | -60.1% |
| Pre-tax income | -125.3 | -78.9 | -29.1 | -41.6 | -34.5 | -30.7 | -23.0 | -15.8 |
| Income taxes | 0.1 | 0.0 | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.9% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% |
| Net income | -125.4 | -78.9 | -28.8 | -40.0 | -31.6 | -30.7 | -23.0 | -15.8 |
| Net margin | -1328.9% | -427.8% | -89.7% | -586.1% | -2963.1% | -4149.2% | -1275.5% | -101.1% |
| |
| Diluted EPS | ($2.07) | ($1.81) | ($0.83) | ($1.54) | ($1.63) | ($1.71) | ($1.48) | ($1.10) |
| Shares outstanding (diluted) | 60.5 | 43.6 | 34.5 | 25.9 | 19.4 | 18.0 | 15.5 | 14.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|